AdoRx raises $10M for adenosine program in cancer; Molecular Partners poaches Regeneron, recruiting Pamela Trail as CSO
→ A day after iTeos raised $75 million to accelerate its research plans on an adenosine program for cancer, a new rival has sprung up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
